Across TCGA pan-cancer cohorts, RSBN1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RSBN1L data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher RSBN1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RSBN1L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, UCEC, and COAD are the cancer types where RSBN1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.272	0.885	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.622	.003	12	view →
COAD	OS	Median	All	0.132	0.674	.001	8	view →
MESO	DFS	Median	All	0.098	0.366	.039	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RSBN1L tumor-vs-normal RNA expression · all RSBN1L data types